No Data
5 Stocks That Could Get a Bump From Activist Investors
Is Pfizer Inc. (PFE) the Best Pharma Dividend Stock to Buy In 2024?
Pfizer Ends Sangamo Partnership for Hemophilia Therapy
Sangamo Down 31% at $1.61 After Pfizer Decision to Terminate Collaboration
Pfizer Options Spot-On: On December 30th, 138.38K Contracts Were Traded, With 3.31 Million Open Interest
Takeda-backed Ascentage Pharma Files for $100M IPO